Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders

European Archives of Psychiatry and Clinical Neuroscience

Volumn 267, Issue 1, 2017, Pages 63-72

  Wu, Bo Jian ^a,b   Lan, Tsuo Hung ^b,c,d  

^a Yuli Hospital   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Predictors of smoking reduction; Schizophrenia; Schizophrenia spectrum disorders; Smoking reduction

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LOXAPINE; NICOTINE PATCH; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; COPING BEHAVIOR; DISEASE ASSOCIATION; DSM-IV; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL HOSPITAL; MENTAL PATIENT; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOEDUCATION; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TREATMENT DURATION; CONTROLLED STUDY; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TAIWAN; THERAPY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; SMOKING CESSATION; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940061821     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-015-0636-7     Document Type: Article

References (77)

1. Beratis S, Katrivanou A, Gourzis P (2001) Factors affecting smoking in schizophrenia. Compr Psychiatry 42(5):393–402
2. Combs DR, Advokat C (2000) Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 46(2–3):129–137
3. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW (1998) Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 33(1–2):113–118
4. Herran A, de Santiago A, Sandoya M, Fernandez MJ, Diez-Manrique JF, Vazquez-Barquero JL (2000) Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 41(2):373–381
5. McCreadie RG, Scottish Comorbidity Study G (2002) Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 181:321–325
6. Bradshaw T, Lovell K, Harris N (2005) Healthy living interventions and schizophrenia: a systematic review. J Adv Nurs 49(6):634–654
7. Corrigall WA (1991) Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86(5):507–510
8. Imperato A, Mulas A, Di Chiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132(2–3):337–338
9. Mereu G, Yoon KW, Boi V, Gessa GL, Naes L, Westfall TC (1987) Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141(3):395–399
10. Dalack GW, Meador-Woodruff JH (1996) Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. [Review] [45 refs]. Schizophr Res 22(2):133–141
11. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70(4):561–570
12. Lyon ER (1999) A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 50(10):1346–1350
13. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, Remington G, Gatley J (2014) Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 48(1):102–110
14. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL (2014) Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res 163(1–3):24–31
15. Lan TH, Chiu HJ, Wu BJ, Hung TH, Hu TM (2007) Readiness to quit and smoking reduction outcomes. Am J Psychiatry 164(5):827–828
16. Chou KR, Chen R, Lee JF, Ku CH, Lu RB (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41(3):321–330
17. Farnam CR (1999) Zyban: a new aid to smoking cessation treatment–will it work for psychiatric patients? J Psychosoc Nurs Ment Health Serv 37(2):36–42 (quiz 43–34)
18. Ziedonis DM, George TP (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23(2):247–254
19. Mitchell AJ, Vancampfort D, De Hert M, Stubbs B (2015) Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry 37(1):14–23
20. Stubbs B, Vancampfort D, Bobes J, De Hert M, Mitchell AJ (2015) How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand 132(2):122–130. doi:10.1111/acps.12412
21. Tsoi DT, Porwal M, Webster AC (2010) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 6:CD007253
22. Tsoi DT, Porwal M, Webster AC (2010) Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 196(5):346–353
23. Kishi T, Iwata N (2015) Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 265(3):259–268
24. George TP, Verrico CD, Picciotto MR, Roth RH (2000) Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 295(1):58–66
25. Procyshyn RM, Ihsan N, Thompson D (2001) A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. Int Clin Psychopharmacol 16(5):291–294
26. Procyshyn RM, Tse G, Sin O, Flynn S (2002) Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 12(1):77–80
27. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K (2006) A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 163(11):1934–1942
28. Brauer LH, Cramblett MJ, Paxton DA, Rose JE (2001) Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology 159(1):31–37
29. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI (2008) A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 63(11):1092–1096
30. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR (2000) Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157(11):1835–1842
31. Barnes M, Lawford BR, Burton SC, Heslop KR, Noble EP, Hausdorf K, Young RM (2006) Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry 40(6–7):575–580
32. Abdullah AS, Lam TH, Chan SS, Hedley AJ (2006) Smoking cessation among Chinese young smokers: does gender and age difference matters and what are the predictors? Addict Behav 31(5):913–921
33. Dino G, Kamal K, Horn K, Kalsekar I, Fernandes A (2004) Stage of change and smoking cessation outcomes among adolescents. Addict Behav 29(5):935–940
34. Prochaska JO, DiClemente CC, Norcross JC (1992) In search of how people change. Applications to addictive behaviors. Am Psychol 47(9):1102–1114
35. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC (2004) Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 65(3):307–311
36. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5):389–409
37. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693
38. Chou KJ, Chen HK, Hung CH, Chen TT, Chen CM, Wu BJ (2015) Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 265(3):249–257. doi:10.1007/s00406-014-0515-7
39. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86(9):1119–1127
40. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276
41. Simpson G, Kunz-Bartholini E (1968) Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst 29(4):269–274
42. Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz ER, Carr CR, Orleans CT, Schoenbach VJ, Biener L, Abrams D et al (1989) Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 44(11):1355–1365
43. Brown H, Prescott R (2006) Applied mixed models in medicine, 2nd edn. Wiley, Hoboken
44. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52(1):53–61
45. Wu BJ, Chen HK, Lee SM (2013) Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia. J Clin Psychopharmacol 33(3):319–328
46. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124(1–2):57–73
47. Meltzer HY (2004) What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 4(1):53–57
48. Karamatskos E, Mulert C, Lambert M, Naber D (2012) Subjective well-being of patients with schizophrenia as a target of drug treatment. Curr Pharm Biotechnol 13(8):1490–1499
49. Swerdlow NR, Bakshi V, Geyer MA (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279(3):1290–1299
50. Depoortere R, Perrault G, Sanger DJ (1997) Potentiation of prepulse inhibition of the startle reflex in rats: pharmacological evaluation of the procedure as a model for detecting antipsychotic activity. Psychopharmacology 132(4):366–374
51. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006) Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63(12):1325–1335
52. George TP, Termine A, Sacco KA, Allen TM, Reutenauer E, Vessicchio JC, Duncan EJ (2006) A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res 87(1–3):307–315
53. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology 178(4):451–460
54. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177(1–2):207–216
55. Thomsen M, Wortwein G, Fink-Jensen A, Woldbye DP, Wess J, Caine SB (2007) Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology 192(1):97–110
56. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL (2007) Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95(1–3):134–142
57. Martinez-Gras I, Rubio G, del Manzano BA, Rodriguez-Jimenez R, Garcia-Sanchez F, Bagney A, Leza JC, Borrell J (2009) The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone. Schizophr Res 115(2–3):215–221
58. Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S (2015) Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia. J Nerv Ment Dis 203(7):486–492. doi:10.1097/NMD.0000000000000317
59. Lowe EJ, Ackman ML (2010) Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 44(4):727–732. doi:10.1345/aph.1M398
60. Cormac I, Brown A, Creasey S, Ferriter M, Huckstep B (2010) A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand 121(5):393–397. doi:10.1111/j.1600-0447.2009.01482.x
61. Ruther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Moller HJ (2014) EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 29(2):65–82
62. Prochaska JO, DiClemente CC (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51(3):390–395
63. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS (1991) The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 59(2):295–304
64. Velicer WF, Norman GJ, Fava JL, Prochaska JO (1999) Testing 40 predictions from the transtheoretical model. Addict Behav 24(4):455–469
65. Abrams DB, Herzog TA, Emmons KM, Linnan L (2000) Stages of change versus addiction: a replication and extension. Nicotine Tob Res 2(3):223–229
66. Perz C, DiClemente C, Carbonari J (1996) Doing the right thing at the right time? The interaction of stages and processes of change in successful smoking cessation. Health Psychol 15(6):462–468
67. Etter M, Mohr S, Garin C, Etter JF (2004) Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophr Bull 30(2):459–468
68. Esterberg ML, Compton MT (2005) Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model. Soc Sci Med 61(2):293–303
69. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC (2001) A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 3(4):397–403
70. Addington J, El-Guebaly N, Campbell W, Hodgins DC, Addington D (1998) Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 155(7):974–976
71. Bohadana A, Nilsson F, Rasmussen T, Martinet Y (2000) Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 160(20):3128–3134
72. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, George TP (2012) A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 73(5):654–660. doi:10.4088/JCP.11m07522
73. Addington J (1998) Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 49(7):925–928
74. Liao DL, Yang JY, Lee SM, Chen H, Tsai SJ (2002) Smoking in chronic schizophrenic inpatients in taiwan. Neuropsychobiology 45(4):172–175
75. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL (2014) Advantages and pitfalls in the application of mixed-model association methods. Nat Genet 46(2):100–106
76. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC (2007) A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 27(4):380–386
77. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR (2015) Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health 15(1):689. doi:10.1186/s12889-015-2055-0